<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05797623</url>
  </required_header>
  <id_info>
    <org_study_id>SHR8735-201</org_study_id>
    <nct_id>NCT05797623</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of Trappa Ethanolamine Tablets Combined With Ciclosporin in the Treatment of Primary Treatment of Non-severe Aplastic Anemia</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, and Open-label, Placebo-controlled Phase II Clinical Study of Trappa Ethanolamine Tablets Combined With Ciclosporin in Patients With Treatment of Non-severe Aplastic Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, and open-label, placebo-controlled phase II&#xD;
      clinical study. In order to evaluate the effectiveness and safety of trappa ethanolamine&#xD;
      tablets combined with ciclosporin in the treatment of patients with non-severe aplastic&#xD;
      anemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 15, 2023</start_date>
  <completion_date type="Anticipated">May 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Full hematological response rate</measure>
    <time_frame>About 13 weeks from the first medication to the evaluation.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Partial hematological response rate and total hematological response rate</measure>
    <time_frame>About 13 weeks from the first medication to the evaluation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematological response rate</measure>
    <time_frame>About 26 weeks from the first medication to the evaluation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time required for the first hematological response</measure>
    <time_frame>About 26 weeks from the first medication to the evaluation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in platelet count relative to the baseline of each visiting point of view</measure>
    <time_frame>About 26 weeks from the first medication to the evaluation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in hemoglobin relative to the baseline of each visiting point of view</measure>
    <time_frame>About 26 weeks from the first medication to the evaluation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in absolute neutrophil count relative to the baseline of each visiting point of view</measure>
    <time_frame>About 26 weeks from the first medication to the evaluation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in reticulocyte count relative to the baseline of each visiting point of view</measure>
    <time_frame>About 26 weeks from the first medication to the evaluation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative proportion of patients who need blood transfusion</measure>
    <time_frame>About 26 weeks from the first medication to the evaluation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative total amount of platelet transfusions</measure>
    <time_frame>About 26 weeks from the first medication to the evaluation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative amount of red blood cell infusions</measure>
    <time_frame>About 26 weeks from the first medication to the evaluation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative proportion of patients with disease progression</measure>
    <time_frame>About 26 weeks from the first medication to the evaluation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Non-severe Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>Trappa ethanolamine tablets combined with ciclosporin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo combined with ciclosporin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trappa ethanolamine tablets ; ciclosporin</intervention_name>
    <description>Trappa ethanolamine tablets combined with ciclosporin</description>
    <arm_group_label>Trappa ethanolamine tablets combined with ciclosporin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo ; ciclosporin</intervention_name>
    <description>Placebo combined with ciclosporin</description>
    <arm_group_label>Placebo combined with ciclosporin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 14-75 years old (including boundary value, whichever is at the time of signing the&#xD;
             informed consent form), Gender is not limited.&#xD;
&#xD;
          2. Diagnosed with non-heavy aplastic anemia within 6 months&#xD;
&#xD;
          3. Life Functional Status (ECOG) Score 0-1&#xD;
&#xD;
          4. Those who understand the research procedures and methods, voluntarily participate in&#xD;
             this experiment, and sign the informed consent form in writing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Total blood cell loss and myelohypoproliferative diseases caused by other reasons&#xD;
&#xD;
          2. Chromosome karyotype analysis during screening shows clonal cytogenetic abnormalities&#xD;
&#xD;
          3. Meet the severe aplastic anemia&#xD;
&#xD;
          4. Paroxysmal sleep hemoglobinuria (PNH) clone â‰¥50% or hemolytic PNH clone&#xD;
&#xD;
          5. Randomly receive ATG, ciclosporin, TPO-R agonists, androgens and other drugs to treat&#xD;
             the relapse without completing the elution&#xD;
&#xD;
          6. Pre-randomized treatment with erythropoietin&#xD;
&#xD;
          7. Pre-randomized use of corticosteroids, G-CSF and GM-CSF treatment&#xD;
&#xD;
          8. People with a history of hematopoietic stem cell transplantation&#xD;
&#xD;
          9. subjects who had deep vein thrombosis, myocardial infarction, cerebral infarction or&#xD;
             peripheral arterial embolism in the first 12 months&#xD;
&#xD;
         10. Previous history of liver cirrhosis or portal hypertension&#xD;
&#xD;
         11. When screening, alanine aminotransferase, barley transaminase, total bilirubin and&#xD;
             blood creatinine are higher than the upper limit of normal value&#xD;
&#xD;
         12. HIV infection or carrier in the past or screening; hepatitis C antibody positive;&#xD;
             hepatitis B surface antigen positive or hepatitis B core antibody positive, and&#xD;
             HBV-DNA test indicates virus replication&#xD;
&#xD;
         13. Patients with randomized bleeding and/or infection that are still uncontrollable after&#xD;
             standardized treatment&#xD;
&#xD;
         14. Uncontrolled hypertension at screening, severe arrhythmia, level III/IV (graded by the&#xD;
             New York Heart Association) congestive heart failure&#xD;
&#xD;
         15. Those who are known or suspected to be contraindicated or highly sensitive to Trappa&#xD;
             ethanolamine API or cyclosporine&#xD;
&#xD;
         16. The subjects had any malignant solid tumors of the organ system in the first 5 years&#xD;
             of screening, regardless of whether they had been treated, metastasis or relapsed,&#xD;
             except for local skin basal cell carcinoma; subjects with blood tumors found in the&#xD;
             past or screening&#xD;
&#xD;
         17. Pregnant or lactating women&#xD;
&#xD;
         18. Male subjects of women of childbearing age or partners of women of childbearing age&#xD;
             refuse to use acceptable contraceptive measures from the period of taking the drug to&#xD;
             28 days after the last time of taking the drug.&#xD;
&#xD;
         19. Randomly participated in other clinical trials and took research drugs in the first 3&#xD;
             months.&#xD;
&#xD;
         20. The researchers believe that there is any situation that may cause the subject to be&#xD;
             unable to complete the study or pose an obvious risk to the subject, or other factors&#xD;
             that reduce the possibility of joining the group.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wei Lu</last_name>
    <phone>0518-82342973</phone>
    <email>wei.lu@hengrui.com</email>
  </overall_contact>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 22, 2023</study_first_submitted>
  <study_first_submitted_qc>March 22, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2023</study_first_posted>
  <last_update_submitted>March 22, 2023</last_update_submitted>
  <last_update_submitted_qc>March 22, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

